A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 25877329)

Published in Nat Rev Cancer on April 16, 2015

Authors

Nancy Ratner1, Shyra J Miller1

Author Affiliations

1: Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA.

Associated clinical trials:

RASopathy Biorepository | NCT04395495

Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 | NCT05238909

Articles citing this

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24

Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer (2016) 0.94

Transforming Cancer Prevention through Precision Medicine and Immune-oncology. Cancer Prev Res (Phila) (2016) 0.93

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol (2016) 0.91

The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90

The Dark Side of Cell Signaling: Positive Roles for Negative Regulators. Cell (2016) 0.82

The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A (2016) 0.79

Neurofibromin Loss of Function Drives Excessive Grooming in Drosophila. G3 (Bethesda) (2016) 0.77

microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). Neurogenetics (2016) 0.76

Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget (2016) 0.76

RASopathy Gene Mutations in Melanoma. J Invest Dermatol (2016) 0.76

Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest (2016) 0.76

The NF1 gene in tumor syndromes and melanoma. Lab Invest (2017) 0.75

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therap Adv Gastroenterol (2016) 0.75

Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder? Int J Mol Sci (2017) 0.75

The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics (2017) 0.75

Cancer of the Peripheral Nerve in Neurofibromatosis Type 1. Neurotherapeutics (2017) 0.75

An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. Sci Rep (2017) 0.75

Targeting brain tumor cAMP: the case for sex-specific therapeutics. Front Pharmacol (2015) 0.75

Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol (2015) 0.75

Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-coupled Affinity Purification/Mass Spectrometry Analysis Revealed a Novel Role of Neurofibromin in mTOR Signaling. Mol Cell Proteomics (2017) 0.75

A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. BMC Genomics (2017) 0.75

The role of nerve microenvironment for neurofibroma development. Oncotarget (2016) 0.75

Comprehensive pharmacological profiling of neurofibromatosis cell lines. Am J Cancer Res (2017) 0.75

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. J Invest Dermatol (2017) 0.75

Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors. Expert Opin Orphan Drugs (2015) 0.75

Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. Cell Death Dis (2016) 0.75

An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors. EBioMedicine (2016) 0.75

Identification and characterization of NF1 splicing mutations in Korean patients with neurofibromatosis type 1. J Hum Genet (2016) 0.75

The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells. Front Oncol (2017) 0.75

Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type I. Biochimie (2017) 0.75

A Novel Frameshift Mutation in Neurofibromin 1 Gene in a Chinese Family with Neurofibromatosis Type 1. Chin Med J (Engl) (2017) 0.75

NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1. Biomol NMR Assign (2017) 0.75

Genetic Analyses of the NF1 Gene in Turkish Neurofibromatosis Type I Patients and Definition of three Novel Variants. Balkan J Med Genet (2017) 0.75

Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. PLoS One (2017) 0.75

Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma. Pediatr Blood Cancer (2016) 0.75

Articles cited by this

(truncated to the top 100)

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91

Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol (1988) 8.61

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA (1997) 8.30

A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10

CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science (2006) 7.68

GEFs and GAPs: critical elements in the control of small G proteins. Cell (2007) 7.32

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell (1990) 6.94

Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51

The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24

Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06

The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84

Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain (1988) 4.69

Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev (2001) 4.68

A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet (1989) 4.42

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23

Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med (1986) 4.18

The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell (1990) 4.12

Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet (1994) 3.97

Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87

Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40

Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev (1994) 3.40

IRA1, an inhibitory regulator of the RAS-cyclic AMP pathway in Saccharomyces cerevisiae. Mol Cell Biol (1989) 3.17

Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet (1996) 3.08

Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet (2000) 3.06

Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01

Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84

An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79

Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol (2006) 2.73

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73

Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr (1994) 2.63

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55

Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42

IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. Mol Cell Biol (1990) 2.40

Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet (1997) 2.39

Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med (2002) 2.39

Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30

Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science (1997) 2.30

Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature (1990) 2.28

Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol (2005) 2.26

An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet (2006) 2.23

Ras history: The saga continues. Small GTPases (2010) 2.18

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17

Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell (2009) 2.12

Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature (1991) 2.10

TORC1 is essential for NF1-associated malignancies. Curr Biol (2007) 2.08

Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A (2010) 2.05

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res (2005) 2.02

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol (2012) 1.95

Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell (2007) 1.92

von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92

Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer (1994) 1.88

A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet (1989) 1.87

Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86

Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85

Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet (2000) 1.84

Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet (1996) 1.83

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81

Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res (2006) 1.80

Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics (2000) 1.79

Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet (2013) 1.71

Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med (2000) 1.71

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68

Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. Am J Med Genet A (2004) 1.67

Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology (2005) 1.65

Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proc Natl Acad Sci U S A (2008) 1.63

Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol (2012) 1.63

Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62

Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60

Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci (2002) 1.58

Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell (2000) 1.58

Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther (2014) 1.57

Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. Cancer Cell (2014) 1.57

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55

The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell (2008) 1.54

Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53

CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell (2013) 1.53

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest (2012) 1.52

Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol (2012) 1.47

Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell (2008) 1.46

Variable expression of neurofibromatosis 1 in monozygotic twins. Am J Med Genet A (2011) 1.45

Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol (2006) 1.42

Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3. J Biol Chem (2000) 1.42

Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol (2008) 1.41

Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet (1999) 1.40

The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron (1992) 1.39

Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science (1997) 1.38

TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer (1994) 1.37

Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet (2011) 1.36